SC 13G 1 ef20027800_sc13g.htm SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

BENITEC BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

08205P209

(CUSIP Number)

April 17, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

Page 1 of 5 Pages

CUSIP No. 08205P209

Page 2 of 5 Pages

1	NAMES OF REPORTING PERSONS
	HBM Healthcare Investments (Cayman) Ltd.

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)☐
	(b)☐
3	SEC USE ONLY


4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands, British West Indies

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			849,893 (1)

		6	SHARED VOTING POWER
			0

		7	SOLE DISPOSITIVE POWER
			849,893 (1)

		8	SHARED DISPOSITIVE POWER
			0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	849,893

10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	☐

11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.99%

12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

(1) See Items 2 and 4

CUSIP No. 08205P209

Page 3 of 5 Pages

Item 1(a).

Name of Issuer:

Benitec Biopharma Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

3940 Trust Way

Hayward, California 94545

Item 2(a).

Name of Person Filing:

HBM Healthcare Investments (Cayman) Ltd. (the “Reporting Person”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

Governors Square

23 Lime Tree Bay Avenue

PO Box 30852

Grand Cayman, KY1-1204, Cayman Islands

Item 2(c).

Citizenship:

Cayman Islands, British West Indies

Item 2(d).

Titles of Classes of Securities:

Common Stock, par value $0.0001 per share (“Common Stock”)

Item 2(e).

CUSIP Number:

08205P209

Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

This Item 3 is not applicable.

Item 4.

Ownership:

Item 4(a).

Amount Beneficially Owned:

As of the date hereof, the Reporting Person may be deemed the beneficial owner of 849,893 shares of Common Stock. This amount includes 841,395 shares of Common Stock and 8,498 shares of Common Stock the Reporting Person has the right to acquire within 60 days upon exercise of pre-funded warrants, at an exercise price of $0.0001 per share (the “Pre-Funded Warrants”), that the Reporting Person purchased pursuant to a securities purchase agreement entered into with the Issuer on April 17, 2024 (the “Private Placement”).

This amount excludes Pre-Funded Warrants to purchase 191,778 shares of Common Stock because the Reporting Person elected to be subject to a 9.99% beneficial ownership limitation, pursuant to which the Reporting Person shall not have the right to exercise any portion of the Pre-Funded Warrants to the extent that after giving effect to such exercise, the Reporting Person would beneficially own in excess of 9.99% of the shares of Common Stock outstanding (the “Blocker”). As such, the Reporting Person may not exercise 191,778 of the Pre-Funded Warrants within 60 days.

Item 4(b).

Percent of Class:

As of the date hereof, the Reporting Person may be deemed the beneficial owner of approximately 9.99% of the shares of Common Stock outstanding.

The percentage set forth herein is calculated based on the sum of (i) 8,498,946 shares of Common Stock outstanding after giving effect to the Private Placement, based on information received from the Issuer, and (ii) 8,498 shares of Common Stock the Reporting Person has the right to acquire within 60 days upon exercise of Pre-Funded Warrants, subject to the Blocker, which have been added to the shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

Item 4(c).

Number of Shares as to which such person has:

	(i) Sole power to vote or direct the vote:	849,893⁽¹⁾
	(ii) Shared power to vote or direct the vote:	0
	(iii) Sole power to dispose or direct the disposition of:	849,893⁽¹⁾
	(iv) Shared power to dispose or direct the disposition of:	0

CUSIP No. 08205P209

Page 4 of 5 Pages

Item 5.

Ownership of Five Percent or Less of a Class.

This Item 5 is not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

This Item 6 is not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

This Item 7 is not applicable.

Item 8.

Identification and Classification of Members of the Group.

This Item 8 is not applicable.

Item 9.

Notice of Dissolution of Group.

This Item 9 is not applicable.

Item 10.

Certification. (if filing pursuant to Rule 13d-1(c))

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

(1)

Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the “Board”). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.

CUSIP No. 08205P209

Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

Dated: April 29, 2024

	HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

	By:	/s/ Jean-Marc LeSieur
	Name:	Jean-Marc LeSieur
	Title:	Managing Director

SIGNATURE PAGE TO SCHEDULE 13G (BENITEC BIOPHARMA INC.)

SEC Form SC 13G filed by Benitec Biopharma Inc.